MRT-2359   Click here for help

GtoPdb Ligand ID: 12629

Synonyms: MRT2359
Compound class: Synthetic organic
Comment: MRT-2359 is a GSPT1 (a.k.a. eRF3a)-targeting molecular glue degrader. It uses a cereblon (CRBN) binding moiety to induce degradation of the translation termination factor GSPT1 (GSPT1; P15170), This mechanism produces an anti-proliferative effect on cancer cells. MRT-2359's chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 114.04
Molecular weight 495.38
XLogP 0.86
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=C(C=C2C(=C1)CN(C3CCC(=O)NC3=O)C2=O)COC(=O)NC4=CC(=CC=C4F)OC(F)(F)F
Isomeric SMILES FC1=CC=C(OC(F)(F)F)C=C1NC(=O)OCC2=CC3=C(CN(C4CCC(=O)NC4=O)C3=O)C=C2
InChI InChI=1S/C22H17F4N3O6/c23-15-4-3-13(35-22(24,25)26)8-16(15)27-21(33)34-10-11-1-2-12-9-29(20(32)14(12)7-11)17-5-6-18(30)28-19(17)31/h1-4,7-8,17H,5-6,9-10H2,(H,27,33)(H,28,30,31)
InChI Key HNTGMIGBGVFOBT-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
MRT-2359 has advanced to clinical evaluation, for efficacy against advanced solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05546268 Study of Oral MRT-2359 in Selected Cancer Patients Phase 1/Phase 2 Interventional Monte Rosa Therapeutics, Inc